Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 17/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.60 |
| ▸ | PDE4A | P27815 | 10/20 | 0.60 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dalfampridine SCHEMBL27988237 | 0.88 | PDE4B (0.49) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL27987890 | 0.85 | PDE4B (0.57) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL23717240 | 0.82 | PDE4B (0.60) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL27968607 | 0.82 | PDE4B (0.62) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL18971899 | 0.82 | PDE4B (0.57) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL1157286 | 0.82 | PDE4B (0.56) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL30476643 | 0.82 | PDE4D (0.56) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL8854690 | 0.82 | PDE4D (0.60) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL23982177 | 0.82 | PDE4D (0.56) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL131011 | 0.82 | PDE4B (0.56) | PDE4BPDE4DPDE4APDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822929-B1 | PROCESS FOR PREPARATION OF ROFLUMILAST | SCINOPHARM (CHANGSHU) PHARMACEUTICALS LTD (CN) | 2017-06-14 | — | — | EP | disclosed |
| US-9233925-B2 | Process for preparation of roflumilast | SCINOPHARM (CHANGSHU) PHARMACEUTICALS, LTD. (CN) | 2016-01-12 | — | — | US | disclosed |
| US-20150274667-A1 | PROCESS FOR PREPARATION OF ROFLUMILAST | SCIANDA (CHANGSHU) PHARMACEUTICALS, LTD. (CN) | 2015-10-01 | — | — | US | disclosed |
| US-8933073-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2015-01-13 | — | — | US | disclosed |
| US-8933073-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2015-01-13 | — | — | US | disclosed |
| US-8865662-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8865662-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2014-05-22 | — | — | US | disclosed |
| WO-2013072938-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF ROFLUMILAST | MYLAN LABORATORIES LTD (IN) | 2013-05-23 | — | — | WO | disclosed |
| US-20120277174-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2012-11-01 | — | — | US | disclosed |
| US-20120277174-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2012-11-01 | — | — | US | disclosed |
| US-20110144075-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-06-16 | — | — | US | disclosed |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-03-03 | — | — | US | disclosed |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-03-03 | — | — | US | disclosed |
| WO-2011018510-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-02-17 | — | — | WO | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| WO-2009106419-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009098320-A2 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277174-A1 | NEW MACROLIDES AND THEIR USE | PDE4A, PDE4B, PDE12 | PDE4B 2/4885PDE4D 5/4885PDE4A 1/4885 |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | PDE4A, PDE12, PDE4B | PDE4B 3/4885PDE4D 6/4885PDE4A 1/4885 |
| US-20150274667-A1 | PROCESS FOR PREPARATION OF ROFLUMILAST | REN, CYP3A5, SULT2A1 | PDE4B 283/4885PDE4D 235/4885PDE4A 319/4885 |
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | PDE4A, PDE4B, PDE12 | PDE4B 2/4885PDE4D 5/4885PDE4A 1/4885 |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | MRPS22, MRPS23, MRPL12 | PDE4B 2412/4885PDE4D 2679/4885PDE4A 1873/4885 |
| US-20110144075-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE3A | PDE4B 2/4885PDE4D 8/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.